Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q2 2019 · 10-Q
Revenue$572.62M$572.62M−0.6% vs Q2 2018 Net Income$598.80M$598.80M+123.4% vs Q2 2018 EPS Diluted$19.86$19.86+123.9% vs Q2 2018 Gross Profit$307,800,000+2.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flowderived$155,402,000+99.6% Free Cash Flowderived$133,188,000+160.4% Margins · derivedGross margin53.8%+1.4 pt vs Q2 2018
Operating margin9.8%+2.2 pt vs Q2 2018
Net margin104.6%+58.0 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 6, 2019 · 37 d after period end